Table 1.
Patient demographics
| Rituximab N=25 |
No Rituximab N=25 |
p value | |
|---|---|---|---|
| Recipient Age (mean, SD) | 41 ± 15 | 48 ± 13 | 0.08 |
| Male Gender (No. patients, %) | 8 (32%) | 7 (28%) | 1.0 |
| Previous Txn (No. patients, %) | 19 (76%) | 7 (28%) | 0.002 |
| Previous Txn ≥ 3 | 5 (20%) | 0 | 0.06 |
| HLA-A;B;DR;DQ Mismatch (mean) | 4.8 | 5.0 | 0.61 |
| Repeat HLA mismatch (No. patients, %) | 20 (80%) | 0 | 0.0001 |
| CDC CPRA1 (mean, median) | 48, 50 | 26, 3 | 0.02 |
| FCXM CPRA (mean, median) | 80, 89 | 60, 60 | 0.02 |
| Crossmatch Strength: (No. patients) | |||
| CDC+ | 2 | 1 | 1.0 |
| FCXM+ | 9 | 11 | 0.77 |
| FCXM−, DSA+ | 14 | 13 | 1.0 |
| Number of DSAs2 (mean, median) | 2.0, 2.0 | 1.7, 1.0 | 0.59 |
| Donor Age (mean, SD) | 38 ± 12 | 46 ± 11 | 0.03 |
| No. Pre-Transplant Plasmapheresis (mean) | 3.7 | 2.3 | 0.08 |
| No. Post-Transplant Plasmapheresis (mean) | 4.1 | 3.9 | 0.81 |
| anti-CD25 Induction (No. patients, %) | 10 (40%) | 12 (48%) | 0.78 |
| Thymoglobulin Induction (No. patients, %) | 15 (60%) | 13 (52%) | 0.78 |
1
Calculated panel reactive antibody (CPRA) was determined for HLA-specific antibodies of sufficient strength to yield a positive cytotoxicity (CDC) or flow cytometric crossmatch (FCXM).
2
Number of donor-specific HLA antibodies (DSAs) prior to desensitization.